Biotech Profile
Minoryx – Only Brain-Penetrating PPAR-Gamma Agonist Reaches European Filing for Fatal Childhood Disease
Addressing an Aggressive Pediatric Disease with No Treatment Options Spanish biotech Minoryx has carved out a critical position in orphan CNS diseases by developing leriglitazone for X-linked adrenoleukodystrophy (X-ALD), a genetic condition where patients in the most aggressive phenotype face
4 August 2025